Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564068 · ClinicalTrials.gov registry record · Early Phase 1
Oxytocin on HR in Sleep Apnea Patient
A Early Phase 1 study, sponsored by George Washington University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02564068 is a Early Phase 1 study that has completed, run by George Washington University. The registered enrollment target is 8 participants.
The verdict
NCT02564068, a Early Phase 1 study, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. OSA is a very prevalent disease with high cardiovascular risk factors, yet this disease remains very poorly treated. This proposal, based on the current literature and new basic science results detailed above on the role of oxytocin in cardiovascular control, will test if oxytocin administration improves adverse cardiovascular events during the recurrent nocturnal apneas in patients with OSA. This project will lay the groundwork and provide preliminary data to obtain NIH funding to test this important hypotheses more thoroughly and in larger clinical trials. This study will explore if intranasal oxytocin has any positive cardiovascular benefits in patients with sleep apnea.
Interventions
- DRUG Oxytocin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-05-22 |
| Est. Completion | 2016-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02564068
The ClinicalTrials.gov registry entry for NCT02564068 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxytocin is the first listed.
NCT02564068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02564068 about?
NCT02564068 is a clinical study titled "Oxytocin on HR in Sleep Apnea Patient". In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. OSA is a very prevalent disease with high cardiovascular risk factors, yet this disease remains very poorly treated. This proposal, based on the current litera...
What is the current status of trial NCT02564068?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2015-05-22. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT02564068?
The interventions under investigation include: Oxytocin (DRUG).
Who is sponsoring clinical trial NCT02564068?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.